Skip to main content
Acrivon Therapeutics, Inc. logo

Acrivon Therapeutics, Inc. — Investor Relations & Filings

Ticker · ACRV ISIN · US0048901096 US Manufacturing
Filings indexed 293 across all filing types
Latest filing 2023-11-17 Director's Dealing
Country US United States of America
Listing US ACRV

About Acrivon Therapeutics, Inc.

https://acrivon.com/

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology. The company's core technology is its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, which uses proteomics to identify the biologic drivers of cancer in individual patients. This platform enables the development of OncoSignature companion diagnostic tests designed to match patients with therapies predicted to be most effective for their specific tumor biology, a method distinct from genomic-based approaches. Acrivon's pipeline focuses on DNA Damage Response and cell cycle regulators. Its lead drug candidate, ACR-368 (prexasertib), is a selective kinase inhibitor in Phase 2 clinical trials for multiple solid tumor types. The pipeline also includes ACR-2316, a dual WEE1/PKMYT1 inhibitor. The company leverages its AP3 platform for internal drug development and for strategic co-development partnerships.

Recent filings

Filing Released Lang Actions
Director's Dealing 2023
Director's Dealing
2023-11-17 English
Director's Dealing 2023
Director's Dealing
2023-11-17 English
Director's Dealing 2023
Director's Dealing
2023-11-17 English
Director's Dealing 2023
Director's Dealing
2023-11-17 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 9, 2023, by Acrivon Therapeutics, Inc. It announces the issuance of a press release with financial results for the quarter ended September 30, 2023, and an updated corporate presentation. The document itself does not contain the financial results or detailed financial statements but rather references these materials as exhibits (99.1 and 99.2). The text explicitly states that the information is "furnished" and not "filed," indicating it is an announcement rather than the report itself. The document length is 3854 characters, which is relatively short and consistent with an announcement rather than a full financial report. Therefore, according to the MENU VS MEAL RULE and the nature of the content, this document should be classified as a Regulatory Filing (RNS), which is the fallback category for such announcements and filings that do not contain substantive financial data themselves.
2023-11-09 English
10-Q
Interim / Quarterly Report Q3 2023
2023-11-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.